AnGes Inc
AJW
Company Profile
Business description
AnGes Inc is a biopharmaceutical company. The company's development projects include - HGF plasmid, NFkB decoy oligonucleotide, and Therapeutic vaccine.
Contact
7-7-15, Saito-asagi
4F, Saito Bio-Incubator
Ibaraki
Osaka567-0085
JPNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
154
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,465.00 | 44.50 | 0.53% |
| CAC 40 | 7,379.40 | 1.34 | -0.02% |
| DAX 40 | 19,985.54 | 76.40 | 0.38% |
| Dow JONES (US) | 42,844.31 | 300.09 | 0.71% |
| FTSE 100 | 8,256.00 | 82.98 | 1.02% |
| HKSE | 19,623.32 | 436.63 | -2.18% |
| NASDAQ | 19,475.97 | 165.18 | 0.86% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,925.40 | 43.77 | 0.74% |
| S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
| SSE Composite Index | 3,262.56 | 89.20 | -2.66% |